PMOS: the new name for PCOS
Key Takeaways
PMOS stands for polyendocrine metabolic ovarian syndrome. It is the new consensus name for the condition previously called polycystic ovary syndrome (PCOS). The name is changing because PCOS is not mainly a disease of “cysts”; it is a multisystem endocrine and metabolic condition that can affect cycles, skin, insulin resistance, fertility, pregnancy risk and long-term health.
What Is PMOS?
PMOS is the proposed new name for PCOS, not a separate diagnosis. A 2026 global consensus process published in The Lancet selected “polyendocrine metabolic ovarian syndrome” because it describes the condition more accurately than “polycystic ovary syndrome”.
The words matter:
- Polyendocrine points to several hormone systems, including androgens, insulin, gonadotropins and ovarian hormones.
- Metabolic recognises insulin resistance, dysglycaemia, lipid changes, weight-related risk, sleep apnoea and long-term cardiometabolic health.
- Ovarian keeps the reproductive and ovulatory part of the condition visible without implying that pathological cysts are the central problem.
For now, many clinics, laboratories, insurance forms and medical records will still say PCOS. During the transition, patients may see both names written together: PMOS, formerly PCOS.
Why Was The Name PCOS Considered Misleading?
The term PCOS suggests that ovarian cysts define the condition, but that is not medically accurate. What ultrasound often shows in PCOS is a high number of small follicles, not dangerous ovarian cysts in the usual sense.
This wording has caused several practical problems. Some patients are told they cannot have PCOS because their ovaries do not show a classic “polycystic” appearance. Others worry that they have a cystic disease requiring surgery. In reality, the condition can be driven by ovulatory disturbance, hyperandrogenism and metabolic features even when ultrasound is not the main diagnostic clue.
The new name is meant to reduce that confusion. It also makes room for the parts of the condition that patients often experience most strongly: irregular cycles, acne or hirsutism, difficulty ovulating, insulin resistance, weight change, anxiety about fertility and pregnancy risks.
Did The Diagnostic Criteria Change?
No. The name change does not, by itself, change the diagnostic criteria. Adult diagnosis still follows the international guideline approach: after excluding other causes, two of three features are generally needed - ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound or elevated AMH where appropriate.
Adolescents are handled more cautiously. The 2023 International Evidence-based Guideline requires both ovulatory dysfunction and hyperandrogenism for a firm adolescent diagnosis, because irregular cycles and acne can be common in the first years after menarche.
The important message is simple: if your previous diagnosis was PCOS, the new terminology does not erase it. It reframes the same condition with a more accurate name.
What Does PMOS Mean For Fertility?
For fertility care, PMOS highlights that ovulation, hormones and metabolic health should be assessed together. Many patients with PMOS have a good ovarian reserve, but ovulation may be irregular or absent. Others ovulate but have hyperandrogenism or metabolic features that still need attention before pregnancy.
In practical terms, a fertility assessment usually reviews:
- cycle pattern and evidence of ovulation;
- androgen symptoms such as hirsutism, acne or androgenic hair loss;
- total/free testosterone, SHBG, AMH, TSH and prolactin where clinically relevant;
- glucose metabolism, HbA1c or oral glucose tolerance testing when indicated;
- pelvic ultrasound findings, interpreted in context rather than in isolation.
If another endocrine condition is present, such as hyperprolactinemia, it should be identified rather than assuming every irregular cycle is PMOS.
Does IVF Treatment Change Because Of PMOS?
The name changes, but IVF principles remain the same: stimulation should be individualised and ovarian hyperstimulation risk should be actively reduced. Patients with PMOS often have high follicle counts and can respond strongly to ovarian stimulation.
For IVF, this usually means a careful protocol rather than an aggressive one:
- a GnRH antagonist protocol is commonly preferred;
- the starting FSH dose is adapted to age, AMH, antral follicle count and previous response;
- a GnRH agonist trigger may be used when OHSS risk is high;
- a freeze-all strategy may be considered if the response is excessive;
- glucose, blood pressure, weight-related risk and pregnancy planning are reviewed before transfer.
The new name may improve communication because it reminds both doctor and patient that PMOS is not just an ovary finding. It is a hormonal, metabolic and reproductive condition.
What Should Patients Do During The Transition?
Patients do not need to repeat their entire workup just because the name has changed. A previous PCOS diagnosis remains clinically meaningful, but it is worth checking whether the assessment covered the full PMOS picture.
At your next appointment, you can ask:
- Which diagnostic features do I have: ovulatory dysfunction, hyperandrogenism, ultrasound/AMH findings, or a combination?
- Have other causes of irregular cycles or high androgens been excluded?
- Do I need metabolic screening before pregnancy or IVF?
- If I am trying to conceive, should we start with ovulation induction or move toward IVF?
- If IVF is needed, what is my OHSS prevention plan?
The best use of the new name is not cosmetic. It is a prompt to make the care plan broader, clearer and more precise.
Frequently Asked Questions
Is PMOS the same as PCOS?
Yes. PMOS is the new consensus name proposed for the condition historically called PCOS. During the transition, many documents will use both names.
Does the new name mean ovarian cysts are not important?
It means they were never the whole story. The ultrasound pattern can still help diagnosis in adults, but PMOS is not defined by harmful cysts. Hormonal and metabolic features are central.
Will my old PCOS diagnosis still be accepted?
Yes. A previous PCOS diagnosis remains clinically relevant. Medical systems may take time to adopt PMOS terminology, especially in coding, laboratory forms and guidelines.
Does PMOS always cause infertility?
No. Many people with PMOS conceive naturally, especially if they ovulate regularly. When ovulation is irregular, ovulation induction or IVF may be used depending on age, duration of infertility, semen analysis, tubal status and previous treatment.
Is PMOS mainly a weight-related condition?
No. PMOS can occur at any body size. Weight and insulin resistance can influence severity in some patients, but they do not explain every case and should not be used to dismiss symptoms.
Should treatment be different now?
Treatment should still follow evidence-based PCOS/PMOS care: cycle management, androgen symptom treatment, metabolic screening, ovulation induction when appropriate, and IVF protocols that reduce OHSS risk. The name change improves accuracy; it does not replace clinical judgement.
Clinical Note
In consultation, the most useful part of this name change is the conversation it opens. When a patient hears “polycystic”, she often imagines cysts that need to be removed; when we explain PMOS, we can discuss ovulation, androgens, insulin resistance and IVF risk in a more accurate way. The name is new, but the need for careful, individualised assessment is the same.
- Dr. Senai Aksoy
Sources
- Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. Published online May 12, 2026.
- Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril. 2023;120(4):767-793.
- World Health Organization. Polycystic ovary syndrome. Updated January 22, 2026.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2004;19(1):41-47.
The content has been created by Dr. Senai Aksoy and medically approved.